Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided content states hepatotoxicity and embryo-fetal toxicity risks for TRACLEER and is directly supported by the label sections for Boxed Warning/Warnngs (hepatotoxicity) and embryo-fetal toxicity (pregnancy contraindication, fetal harm risk, contraception/exclusion of pregnancy). No contradictions or unsafe extrapolations are made relative to the supplied label text.
Category Scores
Accurate Statements
TRACLEER has hepatotoxicity risk requiring monthly liver aminotransferase monitoring and discontinuation criteria for aminotransferase elevations with hepatotoxicity symptoms and/or bilirubin ≥2×ULN; postmarketing reports include rare unexplained hepatic cirrhosis and liver failure.
SECTION 5.1; SECTION 2.1 (measure ALT/AST prior to initiation and monthly); SECTION 2.4 (discontinue criteria); SECTION 5.2 (REMS includes monthly monitoring requirements); SECTION 6 (hepatotoxicity cross-reference).
TRACLEER has embryo-fetal toxicity risk based on animal data, is contraindicated in pregnant females, and requires pregnancy exclusion and contraception with discontinuation when pregnancy is detected.
SECTION 5.3; SECTION 4.1 (contraindication in pregnancy); SECTION 2.1 (exclude pregnancy prior to initiation); SECTION 8.1 (risk summary) ; SECTION 6 (embryo-fetal toxicity cross-reference).
Unsupported Statements
Contradictions
Important Omissions
For hepatotoxicity, the label includes specific details on ALT/AST and bilirubin incidence rates and the REMS enrollment/compliance requirements; these are not enumerated in the provided audit-style text (though the overall risk and monitoring/discontinuation concepts are captured).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The content accurately reflects the label’s hepatotoxicity and embryo-fetal toxicity warnings, including contraindication in pregnancy and monitoring/discontinuation concepts; it does not introduce misleading guidance beyond what is stated in the supplied label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement